Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$6.28 -4.7%	$6.18	$4.65 ▼ $10.24	$105.03M	0.49	72,443 shs	40,413 shs
ERAS Erasca	$1.49 +2.1%	$1.35	$1.01 ▼ $3.45	$422.07M	1.14	1.86 million shs	753,328 shs
KROS Keros Therapeutics	$14.57 +0.9%	$11.85	$9.12 ▼ $72.37	$591.70M	1.39	806,057 shs	689,118 shs
PRTC PureTech Health	$17.66 +2.3%	$17.42	$13.30 ▼ $32.98	$414.57M	1.12	4,666 shs	2,791 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-4.70%	-3.83%	-0.48%	+3.29%	-27.98%
ERAS Erasca	+2.05%	+6.43%	+23.65%	-21.16%	-28.71%
KROS Keros Therapeutics	+0.90%	+1.04%	+52.57%	+27.81%	-74.76%
PRTC PureTech Health	+2.32%	+3.69%	-7.54%	-7.55%	-36.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	2.0133 of 5 stars	3.5	3.0	2.7	0.8	0.0
ERAS Erasca	2.9672 of 5 stars	3.5	2.0	2.2	3.3	1.3
KROS Keros Therapeutics	3.1066 of 5 stars	3.3	2.0	4.2	5.0	0.0
PRTC PureTech Health	1.9806 of 5 stars	3.8	3.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$17.00	170.70% Upside
ERAS Erasca	3.00	Buy	$4.83	224.38% Upside
KROS Keros Therapeutics	2.57	Moderate Buy	$40.33	176.82% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	154.81% Upside

Current Analyst Ratings Breakdown

Latest COYA, PRTC, KROS, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/9/2025	KROS Keros Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$43.00 ➝ $25.00
4/1/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00 ➝ $15.00
4/1/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/26/2025	ERAS Erasca	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/21/2025	ERAS Erasca	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/21/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/20/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.55M	29.55	N/A	N/A	$2.47 per share	2.54
ERAS Erasca	N/A	N/A	N/A	N/A	$2.10 per share	N/A
KROS Keros Therapeutics	$3.55M	166.68	N/A	N/A	$11.09 per share	1.31
PRTC PureTech Health	$4.32M	98.30	N/A	N/A	$16.94 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$7.99M	-$0.98	N/A	N/A	N/A	N/A	-31.63%	-27.76%	5/8/2025 (Estimated)
ERAS Erasca	-$125.04M	-$0.74	N/A	N/A	N/A	N/A	-42.26%	-34.97%	5/14/2025 (Estimated)
KROS Keros Therapeutics	-$152.99M	-$5.01	N/A	N/A	N/A	-27,890.94%	-41.74%	-38.42%	5/6/2025 (Estimated)
PRTC PureTech Health	-$65.70M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest COYA, PRTC, KROS, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ERAS Erasca	-$0.12	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	KROS Keros Therapeutics	$0.1614	N/A	N/A	N/A	$62.01 million	N/A
5/8/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
3/20/2025	Q4 2024	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million
2/26/2025	Q4 2024	KROS Keros Therapeutics	-$1.36	-$1.14	+$0.22	-$1.14	$37.32 million	$3.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.31	15.31
ERAS Erasca	N/A	11.00	11.00
KROS Keros Therapeutics	N/A	19.03	19.03
PRTC PureTech Health	N/A	3.68	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
ERAS Erasca	67.78%
KROS Keros Therapeutics	71.56%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
ERAS Erasca	21.50%
KROS Keros Therapeutics	22.90%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
ERAS Erasca	120	283.27 million	221.94 million	Optionable
KROS Keros Therapeutics	100	40.61 million	31.23 million	Optionable
PRTC PureTech Health	100	24.02 million	22.67 million	Not Optionable

COYA, PRTC, KROS, and ERAS Headlines

Recent News About These Companies

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

May 1 at 11:43 AM | finance.yahoo.com

PureTech to Present Results from Phase 2b ELEVATE…

May 1 at 11:43 AM | pharmiweb.com

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

April 30 at 9:04 PM | seekingalpha.com

PureTech Announces Annual Results for Year Ended December 31, 2024

April 30 at 3:02 AM | businesswire.com

PureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | Benzinga

April 22, 2025 | benzinga.com

PureTech Health plc (NASDAQ:PRTC) Short Interest Down 61.5% in March

April 17, 2025 | marketbeat.com

Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

April 10, 2025 | markets.businessinsider.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

PureTech Health Shares Fall After Nordic Capital Withdraws Offer Plan

April 8, 2025 | marketwatch.com

Nordic Capital steps away from potential PureTech Health buyout

April 7, 2025 | fiercebiotech.com

PureTech Health plc Statement Regarding Press Speculation

April 7, 2025 | businesswire.com

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

March 11, 2025 | finance.yahoo.com

PureTech to Present at the Leerink Partners Global Healthcare Conference

February 25, 2025 | finance.yahoo.com

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via ...

February 12, 2025 | businesswire.com

Trend Tracker for (PRTC)

February 2, 2025 | news.stocktradersdaily.com

PureTech Health Plc (NASDAQ: PRTC)

January 30, 2025 | fool.com

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

January 27, 2025 | finance.yahoo.com

Trading (PRTC) With Integrated Risk Controls

January 10, 2025 | news.stocktradersdaily.com

PureTech Drug Gets FDA Fast-Track Designation for Leukemia

January 9, 2025 | marketwatch.com

PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia

January 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, PRTC, KROS, and ERAS Company Descriptions

Coya Therapeutics NASDAQ:COYA

$6.28 -0.31 (-4.70%)

Closing price 05/1/2025 04:00 PM Eastern

Extended Trading

$5.58 -0.70 (-11.07%)

As of 07:00 AM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Erasca NASDAQ:ERAS

$1.49 +0.03 (+2.05%)

Closing price 05/1/2025 04:00 PM Eastern

Extended Trading

$1.45 -0.04 (-2.68%)

As of 07:00 AM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Keros Therapeutics NASDAQ:KROS

$14.57 +0.13 (+0.90%)

Closing price 05/1/2025 04:00 PM Eastern

Extended Trading

$14.50 -0.06 (-0.45%)

As of 05:02 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

PureTech Health NASDAQ:PRTC

$17.76 +0.50 (+2.92%)

As of 05/1/2025 04:00 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time